Andrew Robbins, Cogent Biosciences CEO
June 7, 2023 07:23 AM EDT
Financing

Co­gent Bio­sciences fol­lows AS­CO da­ta drop for KIT in­hibitor with up­sized $150M pub­lic stock of­fer­ing

Katherine Lewin

News Reporter

Days af­ter a da­ta drop for its KIT in­hibitor at this year’s Amer­i­can So­ci­ety of Clin­i­cal On­col­o­gy meet­ing, Co­gent Bio­sciences an­nounced

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

No­vo Nordisk to phase out its pro­duc­tion of hu­man in­sulin pens glob­al­ly

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times